24-7.is was established 1997, with a great end 2 end knowledge on how to handle this kind of delicate products inside the USA for all parts safety. Why are our prices so low? : We don't deal with middle hands and try to use high quality budget brands. If you are concerned about your safety, our safety then it's highly recommended that you use our services due to our hugh experience. | Please read our customers reviews that will blow your mind. Dismiss
Pfizer Inc. (NYSE:PFE) today announced that the European Commission approved TALZENNA® (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, as monotherapy for the treatment of adult patients with germline breast cancer susceptibility gene (gBRCA)1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-) locally advanced (LA) or metastatic breast cancer (MBC). Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor-positive (HR+) breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.
This approval follows the medicine’s approval by the U.S. Food and Drug Administration (FDA) in October 2018.
5 stars00 %
4 stars00 %
3 stars00 %
2 stars00 %
1 star00 %
Only logged in customers who have purchased this product may write a review.